

**ASX Announcement**

14 May 2026

**BlinkLab to present at Stocks in the Vines  
Investor Access Day**

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), a leading digital healthcare company focused on the development of AI-powered diagnostic technology, is pleased to announce that the Chairman, Mr Brian Leedman will present today at the *Stocks in the Vines – Investor Access Day* in the Yarra Valley, Victoria.

Stocks in the Vines provides ASX-listed growth companies with direct access to a high-conviction audience of active private investors, advisory groups, family offices and small-cap market participants, creating an environment focused on long-term investment opportunities and shareholder engagement.

“Following our recent successful capital raise, I am excited to continue building market awareness of BlinkLab’s compelling investment proposition at a time when families, caregivers and healthcare systems are increasingly challenged by the growing demand for earlier and more accessible autism and ADHD assessment solutions,” said Brian Leedman, Chairman of BlinkLab Limited. “Autism and ADHD represent large and underserved markets where diagnostic pathways remain slow, subjective and resource intensive. Medical consensus supports that earlier diagnosis enables earlier intervention and improved long-term outcomes for children, which is the opportunity BlinkLab is seeking to address through its smartphone-based digital diagnostic platform currently being evaluated in an FDA registrational study in the United States.”

**This announcement has been approved by the Board of Directors.**

For further information please contact:

**Dr Henk-Jan Boele**

Chief Executive Officer

henkjan@blinklab.org

+31 (0) 611 132 247

**Brian Leedman**

Non-Executive Chairman

brian@blinklab.org

+61 (0) 412 281 780

## About BlinkLab Limited (ASX:BB1)

BlinkLab Limited, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism and ADHD. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.